Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
ORGANIZATION
JPMA Regulatory Chief Seeks Balanced Approach on Japanese PI Waivers
Yuji Kashitani, chair of the Regulatory Affairs Committee at the Japan Pharmaceutical Manufacturers Association (JPMA), has cautioned that Japan’s recent shift toward waiving Japanese PI trials should not be misunderstood as making them unnecessary in all cases. “There is a…
To read the full story
Related Article
- JPMA Think Tank Chief Pledges to Back Policy Debates with Evidence
September 26, 2025
- JPMA to Overhaul Guideline for Handling Drug Inquiries This Fall: Consultation Chair
September 25, 2025
- JPMA Publishes TPP Overview to Bridge Academia and Industry: R&D Chair
September 22, 2025
- JPMA Sets Up Multilateral Advocacy Group to Bolster Global Voice: International Affairs Chair
September 19, 2025
- JPMA Launches Task Force on AI and Open Innovation Challenges: IP Chief
September 18, 2025
- JPMA to Broaden Base of Biopharma Talent through On-Site Training: Committee Chair
September 17, 2025
- JPMA to Compile Best Practices on Patient and Public Involvement
September 16, 2025
- JPMA Plans Joint Training with HCPs to Improve Promo Materials: Review Board Chair
September 11, 2025
- JPMA to Step Up Public Outreach, Build Understanding of Pharma, Says PR Head
September 10, 2025
- JPMA Quality Committee Launches Task Force on DX in Commercial Production
September 9, 2025
- JPMA Code & Compliance Chair Stresses Need to Embed Spirit of Revised COP
September 8, 2025
- JPMA ICH Project Chair Sees RWE as Potential Complement to Clinical Trials
September 5, 2025
- Rules for Measuring Industry-Wide Emissions in the Works: JPMA Environment Chief
September 4, 2025
- Clinical Trial Environment Must Match Global Standards, Says JPMA Evaluation Chief
September 2, 2025
- Information Provisioning on Solo Channels Is Duty of Both Makers and Wholesalers: JPMA Distribution Chief
September 1, 2025
- Indicators Needed to Frame Pharma as Growth Market in Japan, Says JPMA Policy Chief
August 29, 2025
ORGANIZATION
- Labor Union Group Submits Request, Urges Drug Pricing Overhaul amid Inflation
December 3, 2025
- Wholesalers Urge Caution on Debating 2% Buffer without Bigger Reform Picture
November 28, 2025
- Labor Federation Files Request for 5% Drug Price Hike with Health Minister
November 28, 2025
- Japan PBSS Launches to Buttress Drug Discovery via Grassroots Networks
November 26, 2025
- Labor Group Presses Lawmakers to Reflect Rising Costs in Drug Prices
November 26, 2025
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…